How Should Patients Overexposed to Nitrates and Nitrites Be Treated and Managed?
Course: WB 2342
CE Original Date: December 5, 2013
CE Renewal Date: December 5, 2015
CE Expiration Date: December 5, 2017
Download Printer-Friendly Version [916 KB]
General principles of supportive care, with attention to removal of the cause, will suffice for most identified cases of methemoglobinemia resulting from nitrates and nitrites. Not all patients require specific antidotal therapy.
For infants, well water used in preparing formula is a primary etiologic suspect. Patients with chronic congenital methemoglobinemia may have adapted to the chronic cyanosis, such that very high levels of methemoglobin (MetHb) are tolerated without any overt symptoms [Wright et al. 1999; Skold et al. 2011]. Proper fluid, electrolyte, and pH balance is vital, especially in infant methemoglobinemia complicated or caused by serious illness [Olsen and McEvoy 1981; DeBaun 2011; Nelson and Hostetler 2003].
To rule out other etiologies, comatose patients may require intravenous naloxone and glucose. Activated charcoal may be administered after ingestion of substances (generally medications or mothballs) known to cause methemoglobinemia (see Table 2) [Lu et al. 1998; McGoldrick and Bailie 1995; Reigart et al. 1982; Bucaretchi et al. 2000; Sillery et al. 2009; Rahman et al. 2012]. For further guidance on activated charcoal use, please consult your poison control center (1-800-222-1222).
Treatment decisions must be made immediately once methemoglobinemia is recognized and confirmed.
Patients who are symptomatic or have significant concurrent problems that compromise oxygen delivery such as
- Heart disease,
- Lung disease,
- Carbon monoxide poisoning, or
may need antidotal treatment at MetHb levels as low as 10% [Skold et al. 2011].
Because MetHb levels are typically reported as a percentage of hemoglobin, symptoms may vary depending on the total hemoglobin level. As an easy to remember guideline, the treatment action level is often considered to be 20% MetHb in symptomatic patients and 30% in asymptomatic patients [Skold et al. 2011; Osterhoudt 2001; Price 1998].
Monitoring of clinical and laboratory parameters for evidence of escalating or rebound methemoglobinemia, worsening oxygen delivery, or possible hemolysis should be performed during treatment [Bradberry 2003; Osterhoudt 2001; Skold et al. 2011].
Methylene blue is an effective antidote for most patients with methemoglobinemia [Skold et al. 2011; McDonagh et al. 2013].
- Methylene blue is provided as a 1% solution (10 milligrams per milliliter (mg/mL).
- The dose is 2 milligrams per kilogram body weight (mg/kg) (0.2 milliliters per kilogram (mL/kg) of a 1% solution) infused intravenously over 3 to 5 minutes.
- The dose may be repeated at 1 mg/kg if MetHb does not resolve within 30 minutes.
Methylene blue should reduce MetHb levels significantly in less than an hour. It does this by acting as a cofactor to increase the activity of NADPH-MetHb reductase [Skold et al. 2011; McDonagh et al. 2013] (See Figure 6).
- Under usual conditions, NADPH-dependent MetHb reductase reduces less than 5% of MetHb to Hb (as the NADH-dependent MetHb reductase is the dominate pathway). However, NADPH-MetHb reductase assumes a major role in the pharmacotherapy of methemoglobinemia with administration of methylene blue [Skold et al. 2011; McDonagh et al. 2013].
Infants with methemoglobinemia resulting from diarrhea and acidosis may improve with aggressive hydration and bicarbonate infusion to correct the acidosis. However, MetHb levels greater than 20% in symptomatic patients should be treated with methylene blue [Wright et al. 1999; Nelson and Hostetler 2003; Skold et al. 2011]. A second dose of methylene blue will be required in only very severe cases or if there is evidence of ongoing MetHb formation [Bradberry 2003; Skold et al. 2011; McDonagh et al. 2013]. The total dose should not exceed 7 mg/kg because the drug by itself is an oxidizing agent [Harvey and Keitt 1983; Skold et al. 2011]. Certain drugs, such as dapsone, create MetHb over a prolonged biologic half-life because of ongoing formation of metabolites. In these situations, some clinicians prefer continuous infusions of methylene blue titrated from a starting rate of 0.1 mg/kg/hour, rather than intermittent bolus therapy [Berlin et al. 1985; Prasad et al. 2008; Skold et al. 2011]. Of note is that Dapsone and sulfonamides may also induce sulfhemoglobinemia which is irreversible lasting the lifetime of the red blood cell with no known antidote [Schmitter 1975; Park and Nagel 1984; Turner et al. 2007; Ashurst et al. 2010; Skold et al. 2011; Denshaw-Burke 2013]. Since sulfhemoglobin molecules do not carry oxygen and have a similar wavelength as MetHb, they can result in a misleading co-oximetry interpretation [Nelson and Hostetler 2003; Denshaw-Burke 2013].
Methylene blue may discolor skin and mucous membranes, making visual interpretation of cyanosis inaccurate. It may also interfere further with standard pulse oximetry readings. After administration of methylene blue, it is prudent to reassess the patient’s clinical status and current MetHb levels before proceeding with repeat doses [Osterhoudt 2001; Skold et al. 2011]. Methylene blue is excreted primarily by the kidneys. Although side effects are uncommon, large rapidly administered doses have been associated with
- Retrosternal chest pain,
- Hypertension, and
Urine will subsequently develop a blue-green discoloration [Goluboff and Wheaton 1961; Skold et al. 2011].
Because glucose is necessary for the effectiveness of methylene blue, normoglycemic patients should receive maintenance amounts of dextrose and hypoglycemic patients should receive standard dextrose therapy to correct hypoglycemia [Wright et al. 1999; McDonagh et al. 2013].
Figure 6. Methylene Blue Pathway, Pharmacodynamics
A stylized diagram showing the mechanisms that can cause methemoglobin production in erythrocytes and the control mechanisms to prevent methemoglobinemia, including methylene blue treatment which requires NADPH from the Pentose Phosphate Pathway.
© PharmGKB; permission for use given by PharmGKB and Stanford University
http://www.pharmgkb.org/pathway/PA165980834 [McDonagh et al 2013]
Glucose-6-phosphate dehydrogenase (G6PD) is estimated to exist in almost 330 million people around the world, with highest prevalence in Africa, the Middle East and Asia [McDonagh et al. 2013]. Known or suspected G6PD deficiency is a relative contraindication to the use of methylene blue [Chan 1996; Wright et al. 1999; Skold et al. 2011; McDonagh et al. 2013].
- G6PD is a key enzyme in the formation of NADPH,
- G6PD-deficient individuals generate insufficient NADPH to efficiently reduce methylene blue to leukomethylene-blue, which is necessary for the activation of the NADPH-dependent MetHb reductase system.
- G6PD-deficient individuals are also prone to methylene blue-induced hemolysis.
- Methylene blue may also add to oxidative hemolysis.
However, many G6PD-deficient patients have only a partial enzyme deficiency. In these patients, methylene blue may still lower MetHb levels, and the resultant hemolysis may be mild. Therefore, methylene blue is still the first-line treatment in G6PD-deficient patients with life-threatening MetHb [Skold et al. 2011; McDonagh et al. 2013]. A lower starting dose of methylene blue (0.3 to 0.5 mg/kg) is recommended. The dose may be titrated upward to reduce MetHb, as necessary. If the patient’s condition worsens, methylene blue treatment should be stopped and exchange transfusion considered [Wright et al. 1999; Skold et al. 2011; McDonagh et al. 2013].
Young infants without G6PD deficiency have developed Heinz body hemolytic anemia at doses as low as 4 mg/kg [Kirsch and Cohen 1980; Rosen et al. 1971; Nelson and Hostetler 2003]. Moreover, in the presence of hemolysis, high dose methylene blue can itself initiate MetHb formation [Bradberry 2003]. Perinatal administration of higher doses of methylene blue (4 mg/kg), given amniotically, has been reported to induce hemolysis and methemoglobinemia in infants without G6PD deficiency [Wright et al. 1999; Nelson and Hostetler 2003].
Clinicians have tried various treatment alternatives for severe, life-threatening methemoglobinemia, especially when the patient responds poorly to methylene blue therapy (i.e. G6PD deficiency, Hemoglobin M) [McKenzie 2010; Skold et al. 2011; McDonagh et al. 2013].
- These treatment options include exchange transfusion and hyperbaric oxygen therapy [Harrison 1977; Mier 1988; Nelson and Hostetler 2003; DeBaun et al. 2011; Skold et al. 2011].
- During treatment in the hyperbaric chamber, sufficient oxygen can be dissolved directly in the blood to support life; reversible binding to hemoglobin is not required [Wright et al. 1998; Hunter et al. 2011; McDonagh et al. 2013].
- Ascorbic acid and vitamin E (alpha-tocopherol) have been investigated, given their role in cellular detoxification, but do not seem promising as treatments for acute poisoning [Bradberry 2003; Skold et al. 2011; McDonagh et al. 2013].
- In vitro efficacy of N-acetylcysteine in reducing methemoglobinemia has been demonstrated [Wright et al. 1998]; however, its use in acute methemoglobinemia requires more study [Skold et al. 2011].
- Cimetidine (P450 inhibitor) has reduced the incidence of methemoglobinemia in patients taking dapsone, but its role in the acute care setting is unclear [Skold et al. 2011].
Exchange transfusion is typically reserved for patients in whom methylene blue treatment is ineffective (i.e. Hemoglobin M) or where contraindicated (i.e. patients on serotonin uptake inhibitors, etc.)[Ramsey et al. 2007; Khavandi et al. 2008].
- Many patients with asymptomatic methemoglobinemia require only supportive care.
- Methylene blue is an effective antidote for most patients with methemoglobinemia.
- For severe methemoglobinemia, or when the patient responds poorly to methylene blue therapy, alternate treatment options include exchange transfusion and hyperbaric oxygen therapy.